MX2020003864A - Anticuerpos humanos contra fel d1 y metodos de uso de los mismos. - Google Patents

Anticuerpos humanos contra fel d1 y metodos de uso de los mismos.

Info

Publication number
MX2020003864A
MX2020003864A MX2020003864A MX2020003864A MX2020003864A MX 2020003864 A MX2020003864 A MX 2020003864A MX 2020003864 A MX2020003864 A MX 2020003864A MX 2020003864 A MX2020003864 A MX 2020003864A MX 2020003864 A MX2020003864 A MX 2020003864A
Authority
MX
Mexico
Prior art keywords
antibodies
fel
allergen
methods
basophils
Prior art date
Application number
MX2020003864A
Other languages
English (en)
Inventor
Jamie Orengo
Andrew J Murphy
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48326501&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2020003864(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of MX2020003864A publication Critical patent/MX2020003864A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16311—Influenzavirus C, i.e. influenza C virus
    • C12N2760/16334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Virology (AREA)
  • Otolaryngology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

La presente invención proporciona anticuerpos que unen al alergénico de gato, Fel d1 composiciones que comprenden los anticuerpos, ácidos nucleicos que codifican a los anticuerpos y los métodos de uso de los anticuerpos. De acuerdo con ciertas modalidades de la invención, los anticuerpos son los anticuerpos monoclonales completamente humanos que unen a Fel d1. Los anticuerpos de la invención son útiles para unir al alergénico Fel d1 in vivo previniendo así la unión del alergénico Fel d1 a IgE preformado en la superficie de los mastocitos o de los basófilos. Al hacer esto, los anticuerpos actúan para prevenir la liberación de histamina y otros mediadores inflamatorios de los mastocitos y/o de los basófilos, mejorando así la respuesta inconveniente al alergénico de gato en individuos sensibilizados. Los anticuerpos de la invención también pueden ser útiles para que los propósitos del diagnóstico determinen si un paciente es alérgico al alergénico de gato Fel d1.
MX2020003864A 2012-05-03 2014-11-03 Anticuerpos humanos contra fel d1 y metodos de uso de los mismos. MX2020003864A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261642083P 2012-05-03 2012-05-03
US201261718044P 2012-10-24 2012-10-24
US201361783312P 2013-03-14 2013-03-14

Publications (1)

Publication Number Publication Date
MX2020003864A true MX2020003864A (es) 2020-08-13

Family

ID=48326501

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2014013371A MX377634B (es) 2012-05-03 2013-05-02 Anticuerpos humanos contra fel d1 y métodos de uso de los mismos.
MX2020003864A MX2020003864A (es) 2012-05-03 2014-11-03 Anticuerpos humanos contra fel d1 y metodos de uso de los mismos.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2014013371A MX377634B (es) 2012-05-03 2013-05-02 Anticuerpos humanos contra fel d1 y métodos de uso de los mismos.

Country Status (33)

Country Link
US (6) US9079948B2 (es)
EP (4) EP3660047B1 (es)
JP (2) JP6400569B2 (es)
KR (1) KR102185516B1 (es)
CN (2) CN104411719B (es)
AR (1) AR090914A1 (es)
AU (2) AU2013256251C1 (es)
BR (2) BR122019023685B1 (es)
CA (1) CA2871077C (es)
CY (2) CY1124023T1 (es)
DK (2) DK3978522T3 (es)
ES (3) ES3049982T3 (es)
FI (1) FI3978522T3 (es)
HR (3) HRP20251429T1 (es)
HU (2) HUE057062T2 (es)
IL (1) IL235121B (es)
IN (1) IN2014DN08767A (es)
JO (1) JO3820B1 (es)
LT (3) LT3978522T (es)
MX (2) MX377634B (es)
MY (3) MY181422A (es)
NZ (2) NZ701124A (es)
PL (3) PL2844672T3 (es)
PT (3) PT3978522T (es)
RS (3) RS62636B1 (es)
RU (1) RU2658491C2 (es)
SG (3) SG10202102919XA (es)
SI (3) SI3978522T1 (es)
SM (3) SMT202000241T1 (es)
TW (2) TW201803901A (es)
UY (1) UY34782A (es)
WO (1) WO2013166236A1 (es)
ZA (3) ZA201407302B (es)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090137416A1 (en) 2001-01-16 2009-05-28 Regeneron Pharmaceuticals, Inc. Isolating Cells Expressing Secreted Proteins
CN102638971B (zh) 2009-07-08 2015-10-07 科马布有限公司 动物模型及治疗分子
AU2012311286B2 (en) 2011-09-19 2018-07-26 Kymab Limited Antibodies, variable domains and chains tailored for human use
US9253965B2 (en) 2012-03-28 2016-02-09 Kymab Limited Animal models and therapeutic molecules
US10251377B2 (en) 2012-03-28 2019-04-09 Kymab Limited Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies
GB2502127A (en) 2012-05-17 2013-11-20 Kymab Ltd Multivalent antibodies and in vivo methods for their production
JO3820B1 (ar) 2012-05-03 2021-01-31 Regeneron Pharma أجسام مضادة بشرية لـ fel d1وطرق لاستخدامها
AR095196A1 (es) 2013-03-15 2015-09-30 Regeneron Pharma Medio de cultivo celular libre de suero
US9788534B2 (en) 2013-03-18 2017-10-17 Kymab Limited Animal models and therapeutic molecules
US11707056B2 (en) 2013-05-02 2023-07-25 Kymab Limited Animals, repertoires and methods
US9783593B2 (en) 2013-05-02 2017-10-10 Kymab Limited Antibodies, variable domains and chains tailored for human use
US10935554B2 (en) 2013-08-23 2021-03-02 Regeneron Pharmaceuticals, Inc. Diagnostic tests and methods for assessing safety, efficacy or outcome of allergen-specific immunotherapy (SIT)
CA2925723A1 (en) 2013-10-01 2015-04-09 Kymab Limited Animal models and therapeutic molecules
TWI754319B (zh) 2014-03-19 2022-02-01 美商再生元醫藥公司 用於腫瘤治療之方法及抗體組成物
ES2809455T3 (es) 2014-11-17 2021-03-04 Regeneron Pharma Métodos para tratamiento tumoral usando anticuerpo biespecífico CD3xCD20
WO2016161010A2 (en) 2015-03-30 2016-10-06 Regeneron Pharmaceuticals, Inc. Heavy chain constant regions with reduced binding to fc gamma receptors
TWI870789B (zh) 2015-08-04 2025-01-21 美商再生元醫藥公司 補充牛磺酸之細胞培養基及用法
CA2995003A1 (en) * 2015-09-08 2017-03-16 Universitat Zurich Compositions against cat allergy
JP7038064B2 (ja) 2016-04-18 2022-03-17 セルデックス セラピューティクス インコーポレイテッド ヒトｃｄ４０に結合するアゴニスト抗体およびその使用
EP3504328A1 (en) 2016-08-24 2019-07-03 Regeneron Pharmaceuticals, Inc. Host cell protein modification
US11352417B2 (en) * 2016-12-22 2022-06-07 Regeneron Pharmaceuticals, Inc. Method of treating an allergy with allergen-specific monoclonal antibodies
JP7112409B2 (ja) 2017-01-24 2022-08-03 ソシエテ・デ・プロデュイ・ネスレ・エス・アー 抗Ｆｅｌ Ｄ１抗体を含む組成物及びヒトのネコアレルギーの少なくとも１つの症状を減少させる方法
BR112020000127A2 (pt) 2017-07-06 2020-07-07 Regeneron Pharmaceuticals, Inc. método para selecionar um hidrolisado de soja, e, glicoproteína
BR112020010615A2 (pt) 2017-12-22 2020-10-27 Regeneron Pharmaceuticals, Inc. produto farmacêutico proteico, método e sistema para caracterizar impurezas de produto farmacêutico proteico e de fármaco de baixo peso molecular, método para produzir um anticorpo, anticorpo, e, usos do método e do sistema
MX2020008095A (es) 2018-01-31 2020-09-24 Regeneron Pharma Sistemas y métodos para caracterizar variantes de tamaño y carga de impurezas de productos farmacológicos.
TWI786265B (zh) 2018-02-02 2022-12-11 美商再生元醫藥公司 用於表徵蛋白質二聚合之系統及方法
KR20200127979A (ko) 2018-02-28 2020-11-11 리제너론 파마슈티칼스 인코포레이티드 바이러스 오염물질을 확인하기 위한 시스템 및 방법
US12259355B2 (en) 2018-03-19 2025-03-25 Regeneron Pharmaceuticals, Inc. Microchip capillary electrophoresis assays and reagents
CA3246952A1 (en) 2018-03-19 2025-10-31 Regeneron Pharmaceuticals, Inc. Microchip capillary electrophoresis assays and reagents
US12253490B2 (en) 2018-03-19 2025-03-18 Regeneron Pharmaceuticals, Inc. Microchip capillary electrophoresis assays and reagents
TW202016125A (zh) 2018-05-10 2020-05-01 美商再生元醫藥公司 用於定量及調節蛋白質黏度之系統與方法
JP2021525070A (ja) 2018-05-18 2021-09-24 チャン ザッカーバーグ バイオハブ， インコーポレイテッド ヒト由来のアレルゲン特異的抗体を単離する方法およびその使用
CN120795059A (zh) 2018-08-27 2025-10-17 瑞泽恩制药公司 拉曼光谱在下游纯化中的应用
US11754569B2 (en) 2018-08-30 2023-09-12 Regeneron Pharmaceuticals, Inc. Methods for characterizing protein complexes
PL3857237T3 (pl) 2019-01-16 2023-07-10 Regeneron Pharmaceuticals, Inc. Sposoby charakteryzowania mostka disiarczkowego
AU2020275406A1 (en) 2019-05-13 2021-11-18 Regeneron Pharmaceuticals, Inc. Improved competitive ligand binding assays
IL291020B2 (en) 2019-09-24 2025-04-01 Regeneron Pharma Systems and methods for use in chromatography and regeneration
US12297451B1 (en) 2019-10-25 2025-05-13 Regeneron Pharmaceuticals, Inc. Cell culture medium
MY207613A (en) 2019-11-25 2025-03-06 Regeneron Pharma Sustained release formulations using non-aqueous emulsions
US11835527B2 (en) 2020-01-21 2023-12-05 Regeneron Pharmaceuticals, Inc. Deglycosylation methods for electrophoresis of glycosylated proteins
US20220064270A1 (en) 2020-08-26 2022-03-03 Regeneron Pharmaceuticals, Inc. Method of treating an allergy with allergen-specific monoclonal antibodies
IL300828A (en) 2020-08-31 2023-04-01 Regeneron Pharma Asparagine feeding strategies to improve cell culture performance and reduce asparagine sequence variants
MX2023006077A (es) 2020-11-25 2023-06-06 Regeneron Pharma Formulaciones de liberacion sostenida mediante emulsificacion por membrana no acuosa.
US12350374B2 (en) 2020-12-17 2025-07-08 Regeneron Pharmaceuticals, Inc. Fabrication of protein-encapsulating microgels
TW202233827A (zh) 2021-01-20 2022-09-01 美商再生元醫藥公司 改良細胞培養中蛋白質效價的方法
AR125585A1 (es) 2021-03-03 2023-08-02 Regeneron Pharma Sistemas y métodos para cuantificar y modificar la viscosidad de proteínas
JP2024509971A (ja) 2021-03-11 2024-03-05 アイジェニックス， インコーポレイテッド アレルギー応答を予測するための方法およびシステム
CA3211302A1 (en) 2021-03-26 2022-09-29 Ross Kenyon Methods and systems for developing mixing protocols
BR112023024984A2 (pt) 2021-06-01 2024-02-20 Regeneron Pharma Tampão de amostra de eletroforese aquosa, método para identificar contaminantes ou impurezas em uma amostra de droga proteica, e, kit
TW202326138A (zh) 2021-09-08 2023-07-01 美商再生元醫藥公司 用於定量抗體及其他含Ｆｃ蛋白之高通量及基於質譜之方法
CA3232463A1 (en) 2021-09-20 2023-03-23 Philip Mellors Methods of controlling antibody heterogeneity
JP2024538673A (ja) 2021-10-07 2024-10-23 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ｐＨモデリング及び制御のシステム及び方法
KR20240090312A (ko) 2021-10-07 2024-06-21 리제너론 파아마슈티컬스, 인크. Ph 미터 보정 및 교정
MX2024005090A (es) 2021-10-26 2024-07-19 Regeneron Pharma Sistemas y metodos para generar agua de laboratorio y distribuir agua de laboratorio a diferentes temperaturas.
CN114113278B (zh) * 2021-11-24 2024-08-02 中国计量科学研究院 一种基于质谱的体外诊断试剂抗体的表位定位方法
EP4444348A4 (en) * 2021-12-08 2025-12-03 Iggenix Inc COMBINATIONS FOR ALLERGY THERAPY
EP4493921A1 (en) 2022-03-18 2025-01-22 Regeneron Pharmaceuticals, Inc. Methods and systems for analyzing polypeptide variants
US20230416349A1 (en) 2022-06-23 2023-12-28 Regeneron Pharmaceuticals, Inc. Methods Of Identifying And Evaluating Cat Allergy Gene Signatures In A Subject By Determining A Stratified Score Based On Gene Expression
CN120418653A (zh) 2022-12-16 2025-08-01 里珍纳龙药品有限公司 评估色谱柱完整性的方法和系统
WO2024158961A1 (en) 2023-01-25 2024-08-02 Regeneron Pharmaceuticals, Inc. Mass spectrometry-based characterization of antibodies co-expressed in vivo
US20240245779A1 (en) 2023-01-25 2024-07-25 Regeneron Pharmaceuticals, Inc. Methods of modeling liquid protein composition stability
WO2024163708A1 (en) 2023-02-01 2024-08-08 Regeneron Pharmaceuticals, Inc. Asymmetrical flow field-flow fractionation with mass spectrometry for biomacromolecule analysis
US20240280551A1 (en) 2023-02-22 2024-08-22 Regeneron Pharmaceuticals, Inc. System suitability parameters and column aging
KR20250165444A (ko) 2023-03-01 2025-11-25 리제너론 파마슈티칼스 인코포레이티드 항-fel d1 항체 제형
WO2024200854A1 (en) 2023-03-31 2024-10-03 Alk-Abelló A/S Allergen binding antibodies suitable for treating tree pollen allergies
TW202508625A (zh) 2023-05-01 2025-03-01 美商再生元醫藥公司 使用苯酚或苯甲醇之多劑量抗體藥物產品
CN117004650B (zh) * 2023-06-25 2024-05-14 山东立菲生物产业有限公司 一种猫皮屑过敏原组分feld1双链二聚体重组蛋白、制备方法及应用
WO2025054406A1 (en) 2023-09-08 2025-03-13 Regeneron Pharmaceuticals, Inc. Methods and systems for assessing chromatographic column integrity
WO2025064403A2 (en) 2023-09-18 2025-03-27 Regeneron Pharmaceuticals, Inc. Methods and systems for developing chromatography protocols
CN121925272A (zh) 2023-09-29 2026-04-24 瑞泽恩制药公司 利用受控成核进行冻干
CN117069865B (zh) * 2023-10-12 2024-03-01 中国农业科学院饲料研究所 一种基于T细胞抗原表位猫过敏原蛋白嵌合肽cFel d 1的原核表达及其卵黄抗体的制备
WO2025085594A1 (en) 2023-10-18 2025-04-24 Regeneron Pharmaceuticals, Inc. Rapid purification of monoclonal antibody from in-process upstream cell culture material
AU2024373307A1 (en) 2023-11-02 2026-05-14 Regeneron Pharmaceuticals, Inc. Methods for reducing lipase activity using stress
WO2025166281A1 (en) 2024-02-01 2025-08-07 Regeneron Pharmaceuticals, Inc. Platform for charge-detection mass spectrometry analysis of aavs
WO2025175164A1 (en) 2024-02-16 2025-08-21 Regeneron Pharmaceuticals, Inc. Methods of producing concentrated formulated drug substances comprising proteins, and concentrated formulated drug substance made by the methods
WO2025194043A1 (en) 2024-03-15 2025-09-18 Regeneron Pharmaceuticals, Inc. Polysorbate and polyoxyethylene sorbitan as excipients for stable protein formulations
CN117964767B (zh) * 2024-03-29 2024-08-06 北京恩泽康泰生物科技有限公司 抗rage抗体、细胞外囊泡及其制备方法和应用
WO2025259840A1 (en) 2024-06-13 2025-12-18 Regeneron Pharmaceuticals, Inc. Methods and systems for scaled chromatography
WO2026025028A1 (en) 2024-07-26 2026-01-29 Regeneron Pharmaceuticals, Inc. Methods of making ultra-high concentrated protein formulations using lyophilization
WO2026060350A1 (en) 2024-09-13 2026-03-19 Regeneron Pharmaceuticals, Inc. Methods of improving photo stability and controlling formation of hmw species in biologic formulations, and biologic formulations produced by the methods
WO2026076201A2 (en) 2024-10-03 2026-04-09 Regeneron Pharmaceuticals, Inc. Systems and methods for producing therapeutic proteins using single pass tangential flow filtration for in-line concentration and volume reduction of production pools
WO2026080597A1 (en) 2024-10-08 2026-04-16 Regeneron Pharmaceuticals, Inc. Sustained delivery of biologics and non-aqueous manufacture of same

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5512283A (en) 1990-07-06 1996-04-30 Allergene, Inc. Methods for the selective suppression of an immune response to dust mite der Pi
CA2128331A1 (en) 1992-01-21 1993-07-22 Julia L. Greenstein Methods for using histamine derivatives as immunomodulators and in immunotherapeutics
EP0675734A4 (en) * 1992-12-21 1997-05-07 Tanox Biosystems Inc ALLERGY SPECIFIC, MONOCLONAL IgA ANTIBODIES AND SIMILAR PRODUCTS FOR ALLERGY TREATMENT.
GB0002386D0 (en) 2000-02-02 2000-03-22 Novartis Nutrition Ag Therapeutic composition
US6849259B2 (en) 2000-06-16 2005-02-01 Symphogen A/S Polyclonal antibody composition for treating allergy
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US20040101920A1 (en) 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
WO2005103081A2 (en) 2004-04-20 2005-11-03 Genmab A/S Human monoclonal antibodies against cd20
PL1868642T3 (pl) * 2005-03-18 2013-10-31 Cytos Biotechnology Ag Białka fuzyjne alergenów kocich i ich zastosowania
US7566456B2 (en) * 2005-06-23 2009-07-28 Haiming Chen Allergen vaccine proteins for the treatment and prevention of allergic diseases
GB0513878D0 (en) * 2005-07-06 2005-08-10 Mars Inc Cat allergen
WO2007065633A1 (en) 2005-12-05 2007-06-14 Imvision Ag Modulation of the immune response by administration of intralymphatic transduction allergen (itag) -molecules
WO2007113633A2 (en) * 2006-04-03 2007-10-11 Pfizer Products Inc. Immunogenic compositions comprising cat allergen fel dl
NZ587107A (en) 2006-06-02 2012-05-25 Regeneron Pharma High affinity antibodies to human il-6 receptor
AT503690A1 (de) * 2006-06-09 2007-12-15 Biomay Ag Hypoallergene moleküle
EP1921142A1 (en) * 2006-11-07 2008-05-14 Cytos Biotechnology AG Selection of human monoclonal antibodies by eukaryotic cell display
RU2448979C2 (ru) * 2006-12-14 2012-04-27 Ридженерон Фармасьютикалз, Инк. Антитела человека к дельта-подобному лиганду-4 человека
CN104497143B (zh) * 2007-03-29 2020-08-25 健玛保 双特异性抗体及其制造方法
JP6071165B2 (ja) * 2007-05-31 2017-02-01 ゲンマブ エー／エス 安定なＩｇＧ４抗体
GB0710529D0 (en) 2007-06-01 2007-07-11 Circassia Ltd Vaccine
RU2491937C2 (ru) * 2007-07-09 2013-09-10 Нестек С.А. Способы уменьшения аллергических реакций, вызванных аллергенами окружающей среды
MY161564A (en) * 2007-08-10 2017-04-28 Regeneron Pharma High affinity human antibodies to human nerve growth factor
JO3340B1 (ar) * 2010-05-26 2019-03-13 Regeneron Pharma مضادات حيوية لـعامل تمايز النمو 8 البشري
CN106267189B (zh) 2010-10-06 2021-02-26 瑞泽恩制药公司 含有抗白介素-4受体(il-4r)的抗体的稳定制剂
JO3820B1 (ar) 2012-05-03 2021-01-31 Regeneron Pharma أجسام مضادة بشرية لـ fel d1وطرق لاستخدامها
US10935554B2 (en) 2013-08-23 2021-03-02 Regeneron Pharmaceuticals, Inc. Diagnostic tests and methods for assessing safety, efficacy or outcome of allergen-specific immunotherapy (SIT)
US11352417B2 (en) 2016-12-22 2022-06-07 Regeneron Pharmaceuticals, Inc. Method of treating an allergy with allergen-specific monoclonal antibodies

Also Published As

Publication number Publication date
NZ733480A (en) 2019-03-29
RS67417B1 (sr) 2025-12-31
MX377634B (es) 2025-03-10
MY181422A (en) 2020-12-21
HUE057062T2 (hu) 2022-04-28
CA2871077A1 (en) 2013-11-07
SG10202102919XA (en) 2021-05-28
EP3660047A1 (en) 2020-06-03
US9475869B2 (en) 2016-10-25
AU2013256251C1 (en) 2018-08-23
SMT202000241T1 (it) 2020-07-08
AU2018203087B9 (en) 2020-03-26
FI3978522T3 (fi) 2025-11-13
US20160376358A1 (en) 2016-12-29
EP3660047B1 (en) 2021-10-13
EP3978522A3 (en) 2022-07-06
ES3049982T3 (en) 2025-12-19
US11174305B2 (en) 2021-11-16
LT3978522T (lt) 2025-11-25
EP3978522A2 (en) 2022-04-06
KR20150005666A (ko) 2015-01-14
JO3820B1 (ar) 2021-01-31
US10047152B2 (en) 2018-08-14
EP2844672A1 (en) 2015-03-11
AU2018203087A1 (en) 2018-05-24
JP2017153491A (ja) 2017-09-07
US12252530B2 (en) 2025-03-18
HK1202123A1 (en) 2015-09-18
SMT202200014T1 (it) 2022-03-21
SG11201406748QA (en) 2014-11-27
RS60282B1 (sr) 2020-06-30
US9079948B2 (en) 2015-07-14
HRP20211932T1 (hr) 2022-03-18
BR122019023685B1 (pt) 2023-01-17
TWI644921B (zh) 2018-12-21
EP3978522B1 (en) 2025-10-01
CN110240651B (zh) 2024-03-08
RS62636B1 (sr) 2021-12-31
LT3660047T (lt) 2021-11-10
KR102185516B1 (ko) 2020-12-02
PT3660047T (pt) 2021-11-30
UY34782A (es) 2013-11-29
TW201803901A (zh) 2018-02-01
SG10201608378UA (en) 2016-11-29
PL2844672T3 (pl) 2020-08-10
EP4653056A3 (en) 2026-05-13
SI2844672T1 (sl) 2020-07-31
US20180305446A1 (en) 2018-10-25
AR090914A1 (es) 2014-12-17
HRP20200652T1 (hr) 2020-07-10
BR112014026852A2 (pt) 2017-07-18
CN104411719B (zh) 2019-05-14
EP4653056A2 (en) 2025-11-26
RU2658491C2 (ru) 2018-06-21
ES2780392T3 (es) 2020-08-25
CY1124023T1 (el) 2022-03-24
IN2014DN08767A (es) 2015-05-22
ZA202202846B (en) 2023-11-29
JP6603269B2 (ja) 2019-11-06
DK3978522T3 (da) 2025-10-27
PL3660047T3 (pl) 2022-02-14
MX2014013371A (es) 2015-02-05
MY164101A (en) 2017-11-30
WO2013166236A1 (en) 2013-11-07
PT2844672T (pt) 2020-04-30
MY195564A (en) 2023-02-02
CY1124819T1 (el) 2022-11-25
IL235121A0 (en) 2014-12-31
TW201406779A (zh) 2014-02-16
AU2013256251B2 (en) 2018-04-12
HRP20251429T1 (hr) 2026-01-02
EP2844672B1 (en) 2020-02-12
DK2844672T3 (da) 2020-04-20
US20220025029A1 (en) 2022-01-27
JP6400569B2 (ja) 2018-10-03
JP2015523962A (ja) 2015-08-20
ZA201407302B (en) 2021-08-25
US10047153B2 (en) 2018-08-14
SI3660047T1 (sl) 2021-12-31
NZ701124A (en) 2017-07-28
ZA202005273B (en) 2023-11-29
ES2898372T3 (es) 2022-03-07
PL3978522T3 (pl) 2026-01-05
SI3978522T1 (sl) 2025-11-28
US20170210790A1 (en) 2017-07-27
LT2844672T (lt) 2020-04-10
AU2018203087B2 (en) 2020-03-12
CA2871077C (en) 2021-08-17
HUE049440T2 (hu) 2020-09-28
CN110240651A (zh) 2019-09-17
IL235121B (en) 2019-06-30
US20130295097A1 (en) 2013-11-07
PT3978522T (pt) 2025-10-17
CN104411719A (zh) 2015-03-11
BR112014026852B1 (pt) 2023-01-03
AU2013256251A1 (en) 2014-11-06
SMT202500396T1 (it) 2025-11-10
RU2014148502A (ru) 2016-06-27
US20150299303A1 (en) 2015-10-22

Similar Documents

Publication Publication Date Title
ZA202202846B (en) Human antibodies to fel d1 and methods of use thereof
PH12019550238A1 (en) Human antibodies to bet v 1 and methods of use thereof
UA104663C2 (xx) Антитіло, що зв'язує cd127$антитело, связывающее cd127
UA111340C2 (uk) Антитіло, яке специфічно зв'язується з tnf-альфа людини
PH12013500564A1 (en) Anti-cd48 antibodies and uses thereof
TW200801041A (en) Antibodies against human IL-22 and uses therefor
EP2558478A4 (en) AT 5 POSITIONS MODIFIED PYRIMIDINES AND THEIR USE
WO2014012001A3 (en) Use of cart19 to deplete normal b cells to induce tolerance
MY171180A (en) Anti-hla-b*27 antibodies and uses thereof
EA201590247A1 (ru) Антитела к siglec-15
MX345730B (es) Células adherentes derivadas del amnios (amdac) para usarse en el tratamiento de enfermedades y trastornos relacionados con el sistema inmunitario.
MY162511A (en) Engineered anti-tslp antibody
SI2928923T1 (sl) Protitelesa proti antigenu 2 dendritičnih celic v krvi in njihova uporaba
EP3453723A3 (en) Anti-asic1 antibodies and uses thereof
MX2012009564A (es) ANTICUERPO NEUTRALIZANTE DE LA INTEGRINA AVß8.
WO2013122544A3 (en) IL-1β NEUTRALIZING HUMAN MONOCLONAL ANTIBODIES
BR112013023513A2 (pt) anticorpos que ligam tgf-alfa e epiregulina
AR117721A2 (es) Anticuerpos humanos para fel d1 y métodos para usarlos
EA201992651A1 (ru) АНТИТЕЛА ЧЕЛОВЕКА К Bet v 1 И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
UA108088C2 (xx) Сконструйоване антитіло проти tslp
UA113833C2 (xx) Зв'язуючі il-1 білки
HK1190415A (en) Humanised anti-cd52 antibodies